Haemonetics (HAE) Aktienübersicht
Haemonetics Corporation, ein Medizintechnikunternehmen, bietet eine Reihe von Lösungen im Bereich der Krankenhaustechnologie an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
HAE Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Haemonetics Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$76.19 |
| 52-Wochen-Hoch | US$87.32 |
| 52-Wochen-Tief | US$47.32 |
| Beta | 0.52 |
| 1 Monat Veränderung | -3.31% |
| 3 Monate Veränderung | 32.92% |
| 1 Jahr Veränderung | 0.89% |
| 3 Jahre Veränderung | -9.30% |
| 5 Jahre Veränderung | 26.31% |
| Veränderung seit IPO | 1,183.20% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 24
HAE: Vascular Closure Optimism Will Face Ongoing Execution And Reporting Restructure Risk
Haemonetics enters this narrative update with a higher Street price target range, highlighted by Citi lifting its target to $70 from $64 and BofA raising its target to $80 from $72. Analysts reference updated medical technology models, a view that vascular closure may have turned a corner, and what they see as conservative guidance with potential upside across all three segments.Narrativ-Update • Jun 08
HAE: Vascular Closure Optimism Will Face Growing Concerns Over Execution Risk
Haemonetics' analyst price targets have shifted higher, with recent moves from $64 to $70 and from $72 to $80, as analysts point to solid sector fundamentals, a perceived turning point in vascular closure, and what they view as more durable plasma upside. Analyst Commentary Recent Street research on Haemonetics shows a mix of supportive and cautious views.Recent updates
Narrativ-Update • Jun 24
HAE: Vascular Closure Optimism Will Face Ongoing Execution And Reporting Restructure Risk
Haemonetics enters this narrative update with a higher Street price target range, highlighted by Citi lifting its target to $70 from $64 and BofA raising its target to $80 from $72. Analysts reference updated medical technology models, a view that vascular closure may have turned a corner, and what they see as conservative guidance with potential upside across all three segments.Narrativ-Update • Jun 08
HAE: Vascular Closure Optimism Will Face Growing Concerns Over Execution Risk
Haemonetics' analyst price targets have shifted higher, with recent moves from $64 to $70 and from $72 to $80, as analysts point to solid sector fundamentals, a perceived turning point in vascular closure, and what they view as more durable plasma upside. Analyst Commentary Recent Street research on Haemonetics shows a mix of supportive and cautious views.Analyseartikel • May 27
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings
The market for Haemonetics Corporation's ( NYSE:HAE ) shares didn't move much after it posted weak earnings recently...Narrativ-Update • May 25
HAE: Vascular Closure And Plasma Upside Will Offset Recent Cautious Repricing
Haemonetics' updated analyst price target has shifted from $64.00 to $62.00 as analysts balance slightly adjusted fair value and profitability assumptions with views that potential upside to guidance in vascular closure and plasma could prove more durable over time. Analyst Commentary Recent Street research on Haemonetics reflects a mix of optimism around vascular closure and plasma, alongside a series of lower price targets that highlight ongoing execution and growth questions.Narrativ-Update • May 09
HAE: New Approvals And Trials Will Support Upside Despite Cautious Repricing
Haemonetics' updated analyst price target reflects a modest reset in expectations, with several firms trimming their targets by $4 to $12 as analysts factor in slightly lower revenue growth assumptions, a marginally higher profit margin outlook, and a small adjustment to the assumed future P/E multiple. Analyst Commentary Recent research shows a cluster of bearish adjustments to Haemonetics' price targets, with several bearish analysts trimming their numbers in close succession.Narrativ-Update • Apr 22
HAE: Pipeline And Product Updates Will Offset Cautious Sector Repricing
Haemonetics' implied fair value price target has been revised to $64 from $70 as analysts factor in updated sector peer multiples, adjustments to revenue growth and margin assumptions, and a slightly higher discount rate following recent Street research updates. Analyst Commentary Recent Street research around Haemonetics reflects a more cautious tone as several bearish analysts trim their price targets and revisit their assumptions on growth, margins, and valuation risk.
Narrativ-Update • Apr 08
HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing
Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.Narrativ-Update • Mar 25
HAE: Vivasure Deal And Pipeline Progress Will Support Future Share Recovery
Analysts have reduced the Haemonetics fair value estimate to $70 from $74. Recent target resets in the group, including Citi's move to $70, reflect updated assumptions around growth, margins and the P/E multiple for the stock.Narrativ-Update • Mar 10
HAE: Vivasure Deal And 2026 Outlook Will Support Earnings Quality
Analysts have modestly adjusted their views on Haemonetics, with several firms trimming price targets by $10 to $18 and one small $1 upward revision. These changes reflect updated assumptions on valuation multiples, while fair value and key model inputs remain broadly unchanged.Narrativ-Update • Feb 23
HAE: Vivasure Acquisition And FY26 Outlook Will Support Margin Recovery
The analyst price target for Haemonetics has been reduced by $3.70, with analysts pointing to a slightly higher discount rate, a lower fair value estimate and some pressure on projected profit margins, even as they continue to apply a higher forward P/E and updated revenue growth assumptions in their models. Analyst Commentary Recent Street research on Haemonetics has been mixed, with several firms trimming their price targets while at least one firm has lifted its target in connection with the Vivasure Medical acquisition.Narrativ-Update • Feb 08
HAE: Vivasure Acquisition Will Drive Execution And Support Future Share Recovery
Analysts have trimmed their fair value estimate for Haemonetics to about $74.00, reflecting mixed Street price target moves that weigh recent target cuts from several firms against at least one increase tied to a favorable view of the Vivasure Medical acquisition. Analyst Commentary Recent Street research around Haemonetics reflects a split view, with several bearish analysts trimming price targets and a smaller group seeing upside tied to the Vivasure Medical acquisition.Narrativ-Update • Jan 25
HAE: Vivasure Deal And Buyback Will Shape Execution And Share Recovery
Analysts have lifted their price target for Haemonetics from about $58 to roughly $74.82, citing recent Street research that points to higher assumed revenue growth, slightly stronger profit margins, a higher future P/E, and supportive views on the Vivasure acquisition and recent earnings execution. Analyst Commentary Recent Street research has centered on two main themes for Haemonetics, the Vivasure acquisition and the company’s latest earnings print.Seeking Alpha • Jan 11
Haemonetics: Re-Rating Complete, Time To Cash In
Summary Haemonetics has rebounded sharply, with shares up 50% in under six months following a modest organic growth guidance hike. Haemonetics' re-rating is now largely complete, as valuation stands at 17x adjusted earnings and low-20s on free cash flow multiples. Recent guidance improvements are mainly currency-driven, with organic growth momentum excluding CSL showing underlying strength. I am turning cautious and actively trimming my position, as shares now appear fairly valued after rapid appreciation. Read the full article on Seeking AlphaNarrativ-Update • Jan 11
HAE: Achievable Hospital Reset And FY26 Outlook Will Support Gradual Recovery
Narrative Update on Haemonetics Analysts have inched up their price target for Haemonetics, with updated fair value rising from about US$90 to roughly US$92, citing recent price target increases, company performance that met or exceeded expectations across segments, and what they view as more achievable guidance and improved credibility on execution and messaging. Analyst Commentary Recent commentary has focused on how Haemonetics is executing against expectations, how realistic its guidance looks, and what that might mean for valuation support and potential growth in the medium term.Analyseartikel • Jan 06
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrativ-Update • Dec 24
HAE: Achievable Hospital Guidance Reset Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $90 from about $86, citing stronger than expected execution across all segments, a more achievable Hospital guidance reset, and an improved long term sales outlook that supports higher growth and valuation assumptions. Analyst Commentary Analysts see the recent quarter as a constructive inflection point for Haemonetics, with improved guidance and execution supporting a modestly higher valuation framework, though some caution remains around sustainability of growth and delivery against new targets.Narrativ-Update • Dec 10
HAE: Broad Outperformance And Achievable Hospital Guidance Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $86 from about $85, citing broad-based outperformance, more achievable Hospital guidance, and an upgraded FY26 sales outlook that supports a gradual recovery in the shares. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the price target increase toward the high $80s reflects growing confidence in the company’s ability to sustain outperformance across all operating segments.Narrativ-Update • Nov 26
HAE: Solid Execution And Achievable Guidance Will Support Measured Share Recovery
Analysts have raised their price target for Haemonetics from $83 to approximately $84.55. They cite solid execution, an improved sales outlook, and increased confidence in the company's guidance and operational credibility.Narrativ-Update • Nov 12
HAE: Upbeat Execution And Reset Guidance Should Drive Share Price Recovery
Haemonetics' analyst price target has been raised from $76.27 to $83.00, as analysts cite improved execution, strong segment performance, and a more optimistic sales outlook as key drivers for the upward revision. Analyst Commentary Following recent quarterly results and the revised price target, analysts have shared both optimistic highlights and points of caution regarding Haemonetics' outlook and valuation.Analyseartikel • Nov 07
A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb
Haemonetics Corporation ( NYSE:HAE ) shares have had a really impressive month, gaining 36% after a shaky period...Narrativ-Update • Oct 28
Execution Challenges Will Shift Outlook For Global Plasma And Hemostasis Expansion
Haemonetics’ analyst price target has been revised lower by analysts to approximately $76 from $77. This change reflects concerns about execution within the Interventional Technologies segment, despite confidence in the company’s long-term value.Narrativ-Update • Oct 14
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The analyst price target for Haemonetics has been lowered by approximately $1.73 to $76.91. Analysts cite ongoing concerns around sales execution and challenges in the Interventional Technologies segment.Analyseartikel • Sep 15
Is Haemonetics Corporation (NYSE:HAE) Trading At A 48% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Haemonetics fair value estimate is US$100 Haemonetics...Narrativ-Update • Aug 08
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18. What's in the News Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index Valuation Changes Summary of Valuation Changes for Haemonetics The Consensus Analyst Price Target has fallen from $92.45 to $85.18.Analyseartikel • Aug 08
Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower
Haemonetics Corporation ( NYSE:HAE ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • Jun 30
Haemonetics (NYSE:HAE) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jun 10
Market Participants Recognise Haemonetics Corporation's (NYSE:HAE) Earnings
Haemonetics Corporation's ( NYSE:HAE ) price-to-earnings (or "P/E") ratio of 20.5x might make it look like a sell right...Analyseartikel • May 10
Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Mar 18
Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Feb 20
Haemonetics: Almost Blood In The Streets
Summary Haemonetics shares have been trading at more appealing levels after a reduction in full-year sales guidance, trading at historically reasonable levels. The company, generating $1.3 billion in annual sales, has seen modest growth, with significant contributions from its plasma and hospital segments. Despite a cautious outlook due to suboptimal positioning in some units, Haemonetics aims for continued growth in 2025, aided by M&A efforts. Shares have fallen to $64, valuing the business at 3 times sales, with adjusted earnings multiples dropping to mid-teens multiple. The appeal is improving here. Read the full article on Seeking AlphaAnalyseartikel • Feb 13
Haemonetics (NYSE:HAE) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by the solid earnings posted by Haemonetics Corporation ( NYSE:HAE ) recently. Our...Analyseartikel • Dec 06
Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings
Haemonetics Corporation's ( NYSE:HAE ) price-to-earnings (or "P/E") ratio of 32.7x might make it look like a strong...Analyseartikel • Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Neues Narrativ • Sep 03
Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth
Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.Analyseartikel • Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analyseartikel • Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Key Insights The projected fair value for Haemonetics is US$167 based on 2 Stage Free Cash Flow to Equity Haemonetics...Seeking Alpha • Jun 21
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter vascular closure, but recent M&A deals have been more questionable. Haemonetics should see revenue reacceleration in FY'26, with long-term revenue growth of 6% to 7% and margin improvement driving a fair value above $100. Read the full article on Seeking AlphaAnalyseartikel • Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 34.7x Haemonetics Corporation ( NYSE:HAE ) may be sending very bearish...Analyseartikel • Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Key Insights Haemonetics' estimated fair value is US$120 based on 2 Stage Free Cash Flow to Equity Haemonetics...Seeking Alpha • Mar 06
Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Summary Haemonetics Corporation has announced a $160 million cash deal to acquire Attune Medical, a manufacturer of esophageal cooling devices. Haemonetics has seen improvements in its business after a tough period during the pandemic, but its share price has lagged. The company's adjusted earnings multiples have fallen below 20 times, making its shares more reasonably priced. Read the full article on Seeking AlphaAnalyseartikel • Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Haemonetics Corporation ( NYSE:HAE ) just reported healthy earnings but the stock price didn't move much. Investors are...Aktionärsrenditen
| HAE | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 1.5% | -1.5% | 0.6% |
| 1Y | 0.9% | -19.9% | 19.5% |
Rendite im Vergleich zur Industrie: HAE übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -19.9 erzielte.
Rendite vs. Markt: HAE hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 19.5 erzielte.
Preisvolatilität
| HAE volatility | |
|---|---|
| HAE Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: HAE hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: HAEDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1971 | 3,009 | Chris Simon | www.haemonetics.com |
Die Haemonetics Corporation, ein Medizintechnikunternehmen, bietet eine Reihe von Lösungen für das Krankenhauswesen an. Das Unternehmen ist in den Segmenten Plasma, Blutzentrum und Krankenhaus tätig. Es bietet automatisierte Plasmasammelsysteme, Software für das Spendermanagement und unterstützende Softwarelösungen wie das NexSys PCS Plasmapherese-Gerätesystem und die dazugehörigen Einwegartikel und Lösungen sowie integrierte Informationstechnologieplattformen für Plasmakunden zur Verwaltung ihrer Spender, Abläufe und Lieferkette und das NexLynk DMS Spendermanagementsystem und Donor360-Tools.
Haemonetics Corporation's Grundlagenzusammenfassung
| HAE grundlegende Statistiken | |
|---|---|
| Marktanteil | US$3.41b |
| Gewinn(TTM) | US$97.31m |
| Umsatz(TTM) | US$1.33b |
35.6x
Kurs-Gewinn-Verhältnis 2.6x
Kurs-Umsatz-VerhältnisIst HAE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| HAE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.33b |
| Kosten der Einnahmen | US$541.16m |
| Bruttogewinn | US$792.87m |
| Sonstige Ausgaben | US$695.56m |
| Gewinn | US$97.31m |
Zuletzt gemeldete Gewinne
Mar 28, 2026
Datum des nächsten Gewinnberichts
Aug 06, 2026
| Gewinn per Aktie (EPS) | 2.14 |
| Bruttomarge | 59.43% |
| Nettogewinnspanne | 7.29% |
| Schulden/Eigenkapital-Verhältnis | 153.8% |
Wie hat sich HAE auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/10 02:41 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/28 |
| Jährliche Einnahmen | 2026/03/28 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Haemonetics Corporation wird von 24 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |
| Raymond Myers | Benchmark Company |